Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDWD
MDWD logo

MDWD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Mediwound Ltd (MDWD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
16.460
1 Day change
-0.66%
52 Week Range
22.500
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Mediwound Ltd (MDWD) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock shows no significant positive catalysts, weak technical indicators, and declining financial performance. It is better to hold off on investing until stronger signals or improvements in fundamentals emerge.

Technical Analysis

The MACD is negatively expanding (-0.0269), RSI is neutral at 40.085, and moving averages are converging, indicating no clear trend. The stock is trading near its S1 support level (16.45) with resistance at 17.198. Overall, the technical indicators suggest a lack of bullish momentum.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The low Open Interest Put-Call Ratio (0.23) indicates a higher interest in calls, but the Option Volume Put-Call Ratio (1.11) shows more puts being traded today, suggesting mixed sentiment.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
1

Positive Catalysts

  • NULL. No significant news, insider trading, or hedge fund activity to act as a positive catalyst.

Neutral/Negative Catalysts

  • The company's financials show a significant YoY revenue drop (-68.03%) in Q4 2025, along with a declining gross margin (-3.69% YoY). Technical indicators are weak, and the stock has a 60% chance of declining in the short term (-0.97% next day, -2.31% next week).

Financial Performance

In Q4 2025, revenue dropped significantly to $1.867M (-68.03% YoY). However, net income improved to -$7.183M (up 83.80% YoY), and EPS improved to -0.56 (up 55.56% YoY). Gross margin declined to 14.89% (-3.69% YoY), indicating operational challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on recent analyst ratings or price target changes. Wall Street sentiment is neutral.

Wall Street analysts forecast MDWD stock price to rise
6 Analyst Rating
Wall Street analysts forecast MDWD stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.570
sliders
Low
25
Averages
30
High
36
Current: 16.570
sliders
Low
25
Averages
30
High
36
H.C. Wainwright
Buy
maintain
$31 -> $36
AI Analysis
2025-11-21
Reason
H.C. Wainwright
Price Target
$31 -> $36
AI Analysis
2025-11-21
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on MediWound to $36 from $31 and keeps a Buy rating on the shares. The company's new manufacturing facility with six-fold increased capacity is on track to begin commercial production in mid-2026, the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
to
Outperform
downgrade
$36 -> $34
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$36 -> $34
2025-06-02
downgrade
Outperform
to
Outperform
Reason
Oppenheimer assumed coverage of MediWound with an Outperform rating with a price target of $34, down from $36. The firm notes the company's Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound's strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx's clinical/commercial potential, the firm adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MDWD
Unlock Now

People Also Watch